API SUPPLIERS

API Suppliers

0

US DMFs Filed

0

CEP/COS Certifications

0

JDMFs Filed

0

Other Certificates

0

Other Suppliers

0

API REF. PRICE (USD / KG)

0

API Market Place

0

INTERMEDIATES

0

DOSSIERS // FDF

USA (Orange Book)

0

Europe

0

Canada

0

Australia

0

South Africa

0

Uploaded Dossiers

0

GLOBAL SALES (USD Million)

U.S. Medicaid

0

Annual Reports

0

FDF Market Place

0

EXCIPIENTS

0

PATENTS & EXCLUSIVITIES

USFDA Orange Book Patents

0

USFDA Exclusivities

0

DIGITAL CONTENT

Blog #PharmaFlow

0

News

0

REF STANDARD

EDQM

0

USP

0

JP

0

Other Listed Suppliers

0

SERVICES

0

Full Screen View

Gyre Therapeutics

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Catalyst Biosciences Announces Completion of Business Combination with Beijing Continent Pharmaceuticals and Implementation of Name Change and Reverse S...

Details:

The combined company will more efficiently conduct clinical research and development of their promising pipeline of product candidates in organ fibrosis and inflammatory diseases, including F351 (hydronidone) for liver fibrosis.

Lead Product(s): Hydronidone

Therapeutic Area: Pulmonary/Respiratory Diseases Product Name: F351

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Beijing Continent Pharmaceuticals

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Merger October 30, 2023

ASK
US

Upload
your Marketing & Sales content

GNI Group

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Catalyst Biosciences Completes First Steps in Reverse Merger Plan

Details:

F351 is a next-generation pirfenidone analog in Phase 3 clinical development for the treatment of HBV associated liver fibrosis in China and the combined company expects to file an IND in the US and commence Phase 2 studies in 2023.

Lead Product(s): Hydronidone

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F351

Highest Development Status: Phase IIIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Catalyst Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition December 27, 2022

ASK
US

Upload
your Marketing & Sales content

GNI Group

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

GNI Group Ltd. Announces Positive Results From the Phase II Study of F351 as Therapy for HBV-related Liver Fibrosis in China

Details:

F351 was generally well tolerated in this study. In patients treated with placebos, 60 mg/tid F351, 90 mg/tid F351, and 120 mg/tid F351, respectively.

Lead Product(s): Hydronidone,Entecavir

Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Product Name: F351

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable August 17, 2020

ASK
US

Upload
your Marketing & Sales content